Table 1

Characteristics of randomized population and subject disposition

1.2 mg Liraglutide1.8 mg LiraglutidePlacebo
Sex (%) (men/women)57/4351/4962/38
Age (years)55 ± 1055 ± 1155 ± 10
Race (%) (C/B/A/I/O)81/15/1/1/283/10/3/1/384/10/2/1/3
Ethnicity (Hispanic or Latino/not)13/8716/8416/84
BMI (kg/m2)33.2 ± 5.433.5 ± 5.133.9 ± 5.2
Duration of diabetes (years)9 ± 69 ± 69 ± 6
Prestudy OAD treatment
    Monotherapy29 (16)29 (16)32 (18)
    Combination therapy149 (84)149 (84)145 (82)
A1C (%)8.5 ± 1.28.6 ± 1.28.4 ± 1.2
FPG [mg/dl (mmol/l)]182 ± 43 (10.1 ± 2.4)185 ± 43 (10.3 ± 2.4)180 ± 47 (10.0 ± 2.6)
SBP (mmHg)129 ± 14.8126 ± 14.2128 ± 14.5
DBP (mmHg)75.8 ± 9.075.2 ± 8.476.2 ± 9.2
Total cholesterol (mmol/l)5.01 ± 1.335.17 ± 1.434.99 ± 1.34
LDL cholesterol (mmol/l)2.82 ± 0.952.96 ± 1.082.77 ± 0.95
VLDL cholesterol (mmol/l)0.74 ± 0.380.76 ± 0.380.71 ± 0.36
HDL cholesterol (mmol/l)1.26 ± 0.321.27 ± 0.311.25 ± 0.28
Triglycerides (mmol/l)2.41 ± 2.242.39 ± 1.882.74 ± 2.80
Free fatty acids (mmol/l)0.51 ± 0.220.55 ± 0.270.52 ± 0.34
Randomized178178177
Completers153 (86)133 (75)121 (68)
Withdrawals25 (14)45 (25)56 (32)
    Adverse events*11 (6)27 (15)6 (3)
        Nausea/vomiting/diarrhea5 (3)19 (11)0
    Ineffective therapy3 (2)3 (2)29 (16)
    Noncompliance4 (2)4 (2)5 (3)
    Other7 (4)11 (6)16 (9)
  • Data are means ± SD or n (%) unless otherwise indicated.

  • *The adverse events row includes nausea/vomiting/diarrhea. A, Asian; B, black; C, Caucasian; I, American Indian; O, other.